Molecular bases of endometrial cancer:: New roles for new actors in the diagnosis and the therapy of the disease

Marta Llauradó; Anna Ruiz; Blanca Majem; Tugce Ertekin; Eva Colás; Núria Pedrola; Laura Devis; Marina Rigau; Tamara Sequeiros; Melania Montes; Marta Garcia; Sílvia Cabrera; Antonio Gil-Moreno; Jordi Xercavins; Josep Castellví; Angel Garcia; Santiago Ramón y Cajal; Gema Moreno; Francesc Alameda; Mónica Vázquez-Levin; José Palacios; Jaime Prat; Andreas Doll; Xavier Matías-Guiu; Miguel Abal; Jaume Reventós

doi:10.1016/j.mce.2011.10.003

Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

Marta Llauradó, Anna Ruiz, Blanca Majem, Tugce Ertekin, Eva Colás, Núria Pedrola, Laura Devis, Marina Rigau, Tamara Sequeiros, Melania Montes, Marta Garcia, Sílvia Cabrera, Antonio Gil-Moreno, Jordi Xercavins, Josep Castellví, Angel Garcia, Santiago Ramón y Cajal, Gema Moreno, Francesc Alameda, Mónica Vázquez-LevinJosé Palacios, Jaime Prat, Andreas Doll, Xavier Matías-Guiu, Miguel Abal, Jaume Reventós^*

^*Autor corresponent d’aquest treball

Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts

55 Cites (Scopus)

Resum

Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.

Idioma original	Anglès
Pàgines (de-a)	244-255
Nombre de pàgines	12
Revista	Molecular and Cellular Endocrinology
Volum	358
Número	2
DOIs	https://doi.org/10.1016/j.mce.2011.10.003
Estat de la publicació	Publicada - 25 de jul. 2012

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1016/j.mce.2011.10.003Llicència: C In Copyright

Altres arxius i enllaços

Link to publication in Scopus

Com citar-ho

Llauradó, M., Ruiz, A., Majem, B., Ertekin, T., Colás, E., Pedrola, N., Devis, L., Rigau, M., Sequeiros, T., Montes, M., Garcia, M., Cabrera, S., Gil-Moreno, A., Xercavins, J., Castellví, J., Garcia, A., Ramón y Cajal, S., Moreno, G., Alameda, F., ... Reventós, J. (2012). Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Molecular and Cellular Endocrinology, 358(2), 244-255. https://doi.org/10.1016/j.mce.2011.10.003

@article{11391131fd0249f0b813e8cf0292056c,

title = "Molecular bases of endometrial cancer:: New roles for new actors in the diagnosis and the therapy of the disease",

abstract = "Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.",

keywords = "Aspirates, Endometrial carcinoma, Mice, Molecular genetics, Target therapy, Treatment",

author = "Marta Llaurad{\'o} and Anna Ruiz and Blanca Majem and Tugce Ertekin and Eva Col{\'a}s and N{\'u}ria Pedrola and Laura Devis and Marina Rigau and Tamara Sequeiros and Melania Montes and Marta Garcia and S{\'i}lvia Cabrera and Antonio Gil-Moreno and Jordi Xercavins and Josep Castellv{\'i} and Angel Garcia and {Ram{\'o}n y Cajal}, Santiago and Gema Moreno and Francesc Alameda and M{\'o}nica V{\'a}zquez-Levin and Jos{\'e} Palacios and Jaime Prat and Andreas Doll and Xavier Mat{\'i}as-Guiu and Miguel Abal and Jaume Revent{\'o}s",

note = "Funding Information: M.LI. is recipient of a predoctoral fellowship from the Spanish Ministry of Innovation and Science ( FI07/00423 ) and E.C. from the Spanish Ministry of Education and Science ( BES-2006-14152 ). A.R. is a recipient of a postdoctoral fellowship from the Generalitat de Catalunya ( 2006BPB10160 ). Funding Information: The authors would like to thank Lisa Piccione for correction of the manuscript. This work has been supported by the Spanish Ministry of Science and Innovation ( SAF 2005-06771 ; SAF 2008-03996 ; SAF 2010-10635-E ; SAF2011-26548 ), AECC Stable Research Groups 2011, CENIT Program ( CENIT/01/2006 ) and RTICC Program ( RTICC RD06/0020/0058 and RD06/0020/1034 ), the Catalan Institute of Health and the Department of Universities and Research, Catalan Government ( 2009SGR00487 , 2005SGR00553 ), the ACCIO Program ( RDITSCON07-1-0001 ), the Foundation La Marato de TV3 ( Grant 050431 ), the IV Grant Fundaci{\'o} Santiago Dexeus Font for Clinical Investigation Projects 2009, the National Programme of Biotecnology ( FIT-010000-2007-26 ), and the European Commission Program Fondo Europeo de Desarrollo Regional (FEDER). ",

year = "2012",

month = jul,

day = "25",

doi = "10.1016/j.mce.2011.10.003",

language = "English",

volume = "358",

pages = "244--255",

journal = "Molecular and Cellular Endocrinology",

issn = "0303-7207",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Llauradó, M, Ruiz, A, Majem, B, Ertekin, T, Colás, E, Pedrola, N, Devis, L, Rigau, M, Sequeiros, T, Montes, M, Garcia, M, Cabrera, S , Gil-Moreno, A, Xercavins, J, Castellví, J, Garcia, A, Ramón y Cajal, S, Moreno, G, Alameda, F, Vázquez-Levin, M, Palacios, J, Prat, J, Doll, A, Matías-Guiu, X, Abal, M & Reventós, J 2012, 'Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease', Molecular and Cellular Endocrinology, vol. 358, núm. 2, pàg. 244-255. https://doi.org/10.1016/j.mce.2011.10.003

TY - JOUR

T1 - Molecular bases of endometrial cancer:

T2 - New roles for new actors in the diagnosis and the therapy of the disease

AU - Llauradó, Marta

AU - Ruiz, Anna

AU - Majem, Blanca

AU - Ertekin, Tugce

AU - Colás, Eva

AU - Pedrola, Núria

AU - Devis, Laura

AU - Rigau, Marina

AU - Sequeiros, Tamara

AU - Montes, Melania

AU - Garcia, Marta

AU - Cabrera, Sílvia

AU - Gil-Moreno, Antonio

AU - Xercavins, Jordi

AU - Castellví, Josep

AU - Garcia, Angel

AU - Ramón y Cajal, Santiago

AU - Moreno, Gema

AU - Alameda, Francesc

AU - Vázquez-Levin, Mónica

AU - Palacios, José

AU - Prat, Jaime

AU - Doll, Andreas

AU - Matías-Guiu, Xavier

AU - Abal, Miguel

AU - Reventós, Jaume

N1 - Funding Information: M.LI. is recipient of a predoctoral fellowship from the Spanish Ministry of Innovation and Science ( FI07/00423 ) and E.C. from the Spanish Ministry of Education and Science ( BES-2006-14152 ). A.R. is a recipient of a postdoctoral fellowship from the Generalitat de Catalunya ( 2006BPB10160 ). Funding Information: The authors would like to thank Lisa Piccione for correction of the manuscript. This work has been supported by the Spanish Ministry of Science and Innovation ( SAF 2005-06771 ; SAF 2008-03996 ; SAF 2010-10635-E ; SAF2011-26548 ), AECC Stable Research Groups 2011, CENIT Program ( CENIT/01/2006 ) and RTICC Program ( RTICC RD06/0020/0058 and RD06/0020/1034 ), the Catalan Institute of Health and the Department of Universities and Research, Catalan Government ( 2009SGR00487 , 2005SGR00553 ), the ACCIO Program ( RDITSCON07-1-0001 ), the Foundation La Marato de TV3 ( Grant 050431 ), the IV Grant Fundació Santiago Dexeus Font for Clinical Investigation Projects 2009, the National Programme of Biotecnology ( FIT-010000-2007-26 ), and the European Commission Program Fondo Europeo de Desarrollo Regional (FEDER).

PY - 2012/7/25

Y1 - 2012/7/25

N2 - Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.

AB - Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.

KW - Aspirates

KW - Endometrial carcinoma

KW - Mice

KW - Molecular genetics

KW - Target therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84861527676&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2011.10.003

DO - 10.1016/j.mce.2011.10.003

M3 - Review article

C2 - 22037169

AN - SCOPUS:84861527676

SN - 0303-7207

VL - 358

SP - 244

EP - 255

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

IS - 2